-

Eurofins Expands Its Network of COVID-19 Testing Centers, Including Airports, Ports, Train Stations and Drive-Through Testing Centers, to Enable Convenient and Safe International Travel

LUXEMBOURG--(BUSINESS WIRE)--As international travel for leisure and business continues to gather momentum, easy access to reliable and cost-effective testing is paramount to ensure safe and hassle-free travel experiences. Alongside further vaccination levels, wide-spread testing for SARS-CoV-2 (COVID-19), and sequencing of positive samples, remains crucial to keep the pandemic under control and potentially avoid breeding grounds for further variants. Eurofins (Paris:ERF) remains fully committed to providing holistic testing services for SARS-CoV-2 (COVID-19), not only through home-testing solutions, but also through an extensive, ever-increasing network of testing centers in travel hubs.

To support millions of passengers in the coming months, Eurofins has rapidly expanded its network of strategically located testing centers to about 1000 across Europe, adding around 500 centers to the network within the last 6 weeks. These sampling stations, in about 20 countries across Europe, cover most major business and tourist hubs. Eurofins intends to keep growing this network and provide unparalleled testing coverage to facilitate European and global travel.

Airports play a major role as travel gateways, and Eurofins has established test centers in 40 airports in Europe. Over 30 testing centers in and near major train stations, such as Brussels-south and Paris Roissy airport train stations, and seaports for cruise ship testing, such as Southampton, Athens and Barcelona complement Eurofins’ existing network of testing centers at travel hubs.

Additionally, Eurofins offers drive-through testing centers on several major highways and airport access roads, recently opening drive-through testing centers in the UK and Germany, as well as the deployment of an increasing number of mobile sampling buses across Europe.

Eurofins continues to invest in laboratory capacity and IT solutions to ensure fast turn-around times for test results (as low as 6 hours, in some cases, after receiving the sample at the laboratory for gold standard PCR tests). Eurofins operates an intuitive web portal in 19 languages, to book testing appointments and access testing information.

For more information visit https://www.covid19testing.eu/.

Notes to editor:

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

Livia Baratta
Investor Relations
Eurofins Scientific SE
ir@eurofins.com

Eurofins Scientific SE

BOURSE:ERF

Release Versions

Contacts

Livia Baratta
Investor Relations
Eurofins Scientific SE
ir@eurofins.com

More News From Eurofins Scientific SE

Eurofins Scientific SE: Weekly Report on Share Repurchases From 09th March to 13th March 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 09/03/2026 FR0014000MR3 10 000 63.1848 CEUX EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 09/03/2026 FR0014000MR3 30 000 63.1292 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 10/0...

Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples

LYON, France--(BUSINESS WIRE)--Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expert...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 02nd March to 06th March 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/03/2026 FR0014000MR3 30 000 67.7739 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/03/2026 FR0014000MR3 10 000 67.7248 CEUX EUROFINS SCIENTIFIC 529900JEHFM...
Back to Newsroom